Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Follicular 3Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Leukemia 2Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1

Interventions

Cyclophosphamide 60Vincristine 57Doxorubicin 54Rituximab 48Prednisone 44Etoposide 35Radiotherapy 34Cytarabine 26Filgrastim 22Methotrexate 21Bleomycin 21Dexamethasone 18Peripheral Blood Stem Cell Transplantation 14Carmustine 14Vinblastine 13Prednisolone 13VAP-cyclo protocol 12Melphalan 12Mitoxantrone 11Mercaptopurine 10Leucovorin 10Dacarbazine 9Ifosfamide 8Granulocyte Colony-Stimulating Factor 8Procarbazine 7Methylprednisolone 7Lenalidomide 7Gemcitabine 7Daunorubicin 7Cisplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma × idelalisib × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡